MONTREAL, QUEBEC--(Marketwire - September 25, 2008) - Thallion Pharmaceuticals Inc. (TSX: TLN) today announced that the first patient has been enrolled in its Phase II trial evaluating TLN-4601 as a second line, monotherapy treatment for glioblastoma multiforme (GBM), an advanced form of brain cancer.
